Immunophotonics, Inc. was recently granted approval by NIH National Cancer Institute (NCI) Institute to transition from Phase I to Phase II Fast-track grant from Small Business Innovative Research (SBIR) for research regarding use of the company’s lead drug candidate, IP-001, in nonclinical models of Hepatocellular Carcinoma (HCC) in conjunction with thermal tumor ablation by microwave. This research is being conducted by Immunophotonics and its collaborators at the University of Louisville Health Sciences Center Research…
